OVA66 promotes tumour angiogenesis and progression through enhancing autocrine VEGF-VEGFR2 signalling

Feifei Song ab1, Qi Chen c1, Wei Rao b, Renfeng Zhang b, Ying Wang b, Hailiang Ge b,*, Qing Wei a,*

* Department of Pathology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, 301 Yanchang Road, Shanghai 200072, China
b Shanghai Institute of Immunology, Department of Immunology and Microbiology, Shanghai Jiaotong University School of Medicine, 227 South Chongqing Road, Shanghai 200025, China
c Division of Gastroenterology and Hepatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, 145 Middle Shandong Road, Shanghai 200001, China

1. Introduction

Signalling through vascular endothelial growth factor A (VEGF) and its receptors (VEGFR1/2/3) on tumour cells stimulates angiogenesis and thus plays a crucial role in the progression, dissemination, and metastasis of numerous cancers, including ovarian and cervical cancers [1]. Indeed, the human VEGF-specific monoclonal antibody bevacizumab and small molecule inhibitors of the tyrosine kinase activity of VEGFRs (e.g., sunitinib, pazopanib) have effectively improved the survival of patients with advanced cervical and ovarian cancer [2-5]. Nevertheless, there remain a number of gaps in our understanding of the intracellular and intercellular mechanisms that regulate VEGF production and signalling in ovarian and cervical cancers.

Many studies have demonstrated that VEGF and VEGFRs are co-expressed in subsets of tumour cells, and contributes to tumorigenesis and angiogenesis [6]. Classically, VEGF secreted by tumour cells acts in a paracrine manner to stimulate angiogenesis via interaction with VEGFRs on endothelial cells. However, tumour cell-derived VEGF also functions as an autocrine factor to regulate cancer cells. Recent studies have shown that VEGF can promote cell proliferation, migration, invasion and survival through an autocrine activation of VEGFR1, VEGFR2 and NRP1 [6-17]. Autocrine VEGF-VEGFR signalling also stimulates VEGF secretion, thus sustaining an autocrine feed-forward loop in the tumour cells [10-12].

Ovarian cancer-associated antigen 66 (OVA66, Hugo Gene Nomenclature Committee: 24306), also known as NUDC Domain Containing 1 (NUDCD1) and Chronic Myelocytic Leukaemia Tumour Antigen 66 (CML66), one of the highly immunogenic proteins known as a cancer/
testis antigens, was first identified by serological analysis of recombinant cDNA expression libraries [18]. Since then, OVA66 has been shown to be overexpressed in multiple tumours and cell lines [19,20]. Previous research in our laboratory demonstrated that OVA66 silencing in HeLa cells inhibited cell proliferation, migration, and invasion in vitro and slowed xenograft growth in nude mice [20]. In NIH3T3 fibroblasts, OVA66 overexpression induces oncogenic transformation by hyperactivating the phosphoinositide 3-kinase (PI3K)–AKT and ERK1/2 signalling pathway [21]. In human ovarian and cervical cancer cells, the effects of OVA66 are at least partially dependent on signalling through the insulin-like growth factor 1 receptor [22]. Intriguingly, inhibition of OVA66 expression in HeLa cells causes significant downregulation of VEGF expression [20]; however, whether or how this might occur in tumour cells is unknown.

To address this knowledge gap, we overexpressed or silenced OVA66 expression in human ovarian and cervical cancer cell lines and examined the effects on VEGF secretion and angiogenesis in vitro and in vivo. We found that OVA66 overexpression increased VEGF secretion, enhanced the effect of VEGF on proliferation, migration, and angiogenesis of cancer cells in vitro, as well as enhanced tumour growth and metastasis formation in mouse models. Moreover, we demonstrated that the mechanism of action of OVA66 involves promotion of an autocrine feed-forward loop of VEGF–VEGFR2 signalling, and that these effects are attenuated by treatment with the receptor tyrosine kinase inhibitor sunitinib. Thus, our data identify a novel role for OVA66 in promoting tumour growth and progression via amplification of autocrine VEGF–VEGFR2 signalling.

2. Materials and methods

2.1. Cell culture and construction of stable cell lines

Human ovarian cancer cell lines (SKOV3 and HO8910), human cervical cancer cell lines (HeLa and SiHa), and human umbilical vein endothelial cells (HUVECs) were purchased from the Cell Bank of the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). Cell identity was confirmed by short tandem repeat analysis, and mycoplasma tests were negative. All cells were maintained in Dulbecco's modified Eagle's medium (DMEM; HyClone, USA) supplemented with 10% foetal bovine serum (FBS; Gibco, USA). Cell lines with stable knockdown or overexpression of OVA66 were established as previously described [23]. Briefly, OVA66-knockdown or control cells were generated by infection with retrovirus encoding OVA66-specific (OVA66-shRNA) or control short hairpin RNAs (NC-shRNA) in the presence of 4 μg/ml polybrene. Cells were selected by culturing for 3 days in medium containing a lethal concentration of puromycin and then for 1 week in 0.5 μg/ml puromycin. Resistant single cell colonies were isolated and expanded for further study. OVA66-overexpressing or control cells were generated by transfection with pIRESpuro3-OVA66 or empty plasmid (Clontech, USA) using Lipofectamine 2000 (Invitrogen, USA), and stable cell lines were selected with puromycin as described above.

2.2. Cell proliferation and VEGF secretion assays

Cell proliferation was measured using a Cell Counting Kit-8 (Dojindo, Japan). Tumour cell production of VEGF was measured using a human VEGF QuantiKine ELISA Kit (R&D Systems, MN) according to the manufacturer's instructions. In brief, equal number of cancer cells were seeded in 6-well plates and serum starved (medium lacking FBS) for 24 h. The cells were then treated for 2 h with 30 ng/ml of recombinant human (rh) VEGF165 (PeproTech, UK) in serum-free medium containing 10 μM Sunitinib (Calbiochem, CA, USA) or vehicle (dimethyl sulfoxide, DMSO) for 2 h. The cells were then incubated with fresh serum-free medium for an additional 24 h. The culture supernatants were collected and analysed for secreted VEGF by ELISA.

2.3. Preparation of conditioned medium and HUVEC tube formation assay

Cancer cells with stable OVA66 knockdown or overexpression were cultured to 80% confluency in complete medium, washed, and serum starved for 24 h. The culture supernatant (conditioned medium) was then collected and filtered through a 0.22-μm filter (Millipore). HUVECs were serum starved for 3–6 h, resuspended in conditioned medium supplemented with 1% FBS, and added (6 × 10³ cells/well) to a 96-well plate pre-coated with 60 μl/well of growth factor-reduced Matrigel (# 354230; BD Biosciences, Sweden). The plates were incubated at 37 °C for 6 h, and the capillary network was then imaged under a light microscope and photographed. The number of branch points in three random fields of view per well were counted.

2.4. Cell migration assay

Cell migration assays were performed using 6.5-mm diameter Transwell chambers (8-μm pore size, BD Biosciences) according to the manufacturer's instructions. Cancer cells were resuspended in 200 μl serum-free medium supplemented with or without 30 ng/ml rhVEGF DMEM, and/or sunitinib (10 μM). The lower chambers were filled with 600 μl medium containing 10% FBS. The plates were incubated at 37 °C for 6 h, the membranes were rinsed with PBS, and the cells on the upper membrane side were removed using cotton-tipped swabs. The migrated cells on the lower side were fixed and stained with crystal violet (Beyotime Biotechnology, China). The membranes were visualised under a light microscope (Olympus, Japan) at 200× magnification and photographed. The number of cells in five randomly selected fields per well were counted and averaged.

2.5. Animal experiments and tumour histology

For the mouse xenograft experiments, OVA66-overexpressing HO8910 cells or OVA66-knockdown HeLa cells were injected subcutaneously into the flank of female nude mice obtained from SLAC Laboratory Animal Co. Ltd. (Shanghai, China) (3–4 weeks of age) at 4 × 10⁶ cells per mouse. Tumour size was monitored twice per week and the volume was calculated using the formula: V = width² × length/2 (mm³). After 4 weeks, the mice were euthanized and the tumours were removed for analysis. For metastasis assays, OVA66-knockdown HeLa cells (10⁶ cells per mouse) were injected via the tail vein into nude mice. The animals were randomised, divided into two groups (n = 10/group), and administered either 100 mg/kg sunitinib (Sutent, Pfizer) or vehicle (saline) via daily oral gavage. The mice were euthanized and the lungs were removed and processed for histology. In brief, the harvested organs and primary tumours were fixed, embedded in paraffin, and stained with haematoxylin and eosin or processed for immunohistochemical staining. All animal protocols were reviewed and approved by the Ethics Review Committee for Animal Experimentation at Shanghai Tenth People’s Hospital.

2.6. Receptor tyrosine kinase signalling antibody array

To explore the molecular mechanism by which VEGF signals in OVA66 cells, we used a Human Receptor Tyrosine Kinase Phosphorylation Antibody Array G1 (RayBiotech, USA), which measures the relative levels of phosphorylation of 71 human receptor or non-receptor tyrosine kinases. Briefly, SKOV3 cells transfected with OVA66-shRNA or NC-shRNA (2 × 10⁶/sample) were serum starved for 6 h and then incubated with medium containing 10% FBS for 1 h. Cells were then harvested and processed according to the kit instructions. All experiments were performed according to the manufacturer's
instructions. The signal intensities were quantified with Photoshop CS2 software (Adobe, USA). Positive and negative controls were included to normalise the results.

2.7. Analysis of VEGFR2 signalling

Cancer cells were seeded in 6-well plates overnight, serum starved for 24 h, and then treated with or without rhVEGF for the indicated times. For some experiments, the cells were treated with DMSO or sunitinib (10 μM) for 1 h before addition of rhVEGF. After incubation, the cells were rinsed twice with PBS and lysed in M-PER buffer (Thermo Scientific, USA) containing protease and phosphatase inhibitor cocktails (Thermo Scientific). Protein in the lysates was quantified using a BCA Protein Assay Reagent Kit (Thermo Scientific). Samples were then analysed by western blotting (see below). The following primary antibodies were purchased from Cell Signaling Technology (USA): VEGFR2 (#9698, RRID: AB_11178792), phosphorylated (p)-VEGFR2 (Tyr1175) (#4278, RRID: AB_331377), ERK1/2 (#4695, RRID: AB_390779), p-ERK1/2 (#4370, RRID: AB_2315112), Akt (#4685, RRID: AB_2225340), p-AKT (#4060, RRID: AB_2341228), p-FAK (#8556, RRID: AB_10891442), p-P38 (#4511, RRID: AB_2139682), p-PLCγ (#8713, RRID: AB_10890863), p-SRC (#6943, RRID: AB_10013641), and β-actin (#3060, RRID: AB_2242334). Primary VEGFR2 antibody from Abcam (ab39256, RRID: AB_883437) was also used. A primary anti-OVA66 antibody was obtained from Santa Cruz Biotechnology (USA; #sc-271650, RRID: AB_10708575).

2.8. Western blot analysis

Proteins in cell lysates (40 μg protein per sample) were resolved by SDS-PAGE analysis and transferred to PVDF membranes (Bio-Rad, USA). The membranes were blocked by incubation in 5% non-fat milk for 1 h at room temperature and then incubated with the primary antibodies at 4 °C overnight. After washing three times in Tris-buffered saline containing 0.1% Tween, the membranes were incubated with horseradish peroxidase-conjugated secondary antibody (KPL, USA) for 1 h at room temperature and then incubated with the primary antibodies at 4 °C overnight. After washing three times in Tris-buffered saline containing 0.1% Tween, the membranes were incubated with horseradish peroxidase-conjugated secondary antibody (KPL, USA) for 1 h at room temperature. Protein bands were detected with Enhanced Chemiluminescence reagent (Millipore, USA).

2.9. Bioinformatic analysis

The Gene Expression Profiling Interactive Analysis online tool (http://geopia.cancer-pku.cn) was used to explore the relationship between OVA66 and VEGF expression in cervical and ovarian cancer specimens [23,24]. Genes A and B were set as “NUCD1” and “VEGFA”, and the datasets “Cervical squamous cell carcinoma and endocervical adenocarcinoma” and “Ovarian serous cystadenocarcinoma” were selected. Spearman’s correlation coefficient was selected for analysis.

2.10. Ovarian cancer tissue microarray (TMA) and immunohistochemistry (IHC)

A tissue microarray (TMA) containing 5 normal ovarian tissues and 94 ovarian cancer tissues was purchased from Shanghai Super Biotech company (Shanghai, China). TMA sections (4 μm thick) were rehydrated in a graded series of alcohol and, heated for 20 min at 95 °C in 10 mM sodium citrate buffer (pH 6.0) for antigen retrieval. After cooling, the sections were incubated overnight at 4 °C with a mouse monoclonal antibody against OVA66 (CML66 C-4, #sc-271650; Santa Cruz Biotechnology). Antibody binding was detected using an IHC kit (Gene Tech, China; #GK600505). Quantification of immunostaining was based on the percentage of positive cells and the intensity of staining, and was independently evaluated by two clinical pathologists who were blinded to sample identity. The final staining score was obtained by multiplying the intensity and percentage scores. The median score was used to dichotomise the tumour biopsies into low and high OVA66 expression groups.

2.11. Statistical analysis

All analyses were performed with SPSS version 20.0 (SPSS Inc., USA). Between-group differences were evaluated using Student’s t-test for continuous variables and Pearson’s χ², Pearson’s corrected χ², or Fisher’s exact test for categorical variables, as appropriate. Data are presented as the mean ± standard deviation (SD). Pairwise gene correlation analysis was performed using Spearman’s correlation statistics. All P values were two-sided, and P < .05 was considered statistically significant.

3. Results

3.1. OVA66 overexpression in cancer cells enhances VEGF secretion and angiogenesis in vitro

Previous cDNA microarray analyses revealed that OVA66 knockdown markedly reduces the expression of several metastasis-related genes [20], including VEGF. To determine whether OVA66 regulates VEGF expression in ovarian and/or cervical cancer, we knocked down or overexpressed OVA66 in HeLa, SiHa (cervical), HO8910, and SKOV3 (ovarian) cancer cell lines. Western blot analysis confirmed efficient inhibition and overexpression of OVA66 in the appropriate cell lines (Fig. 1A). VEGF protein in the cell supernatants was quantified by ELISA and found to be significantly reduced and enhanced by OVA66 knockdown and overexpression, respectively (Fig. 1B). Because tumour-secreted VEGF can promote endothelial cell angiogenesis in a paracrine manner [11], we also assessed tube formation by HUVECs after treatment with conditioned medium collected from OVA66-knockdown or -overexpressing cells. The results indicate that conditioned medium from OVA66-overexpressing cells significantly promoted tube formation (Fig. 1C). However, addition of recombinant OVA66 protein itself had no effect on either VEGF production by cancer cells or the angiogenic ability of HUVECs (Supplemental Fig. 1). Moreover, OVA66 was not detected in the conditioned medium from cancer cells (data not shown), suggesting that OVA66 was not a secreted protein, and might play its role within cells. Taken together, these data indicate that OVA66 plays a role in promoting VEGF secretion by tumour cells, which as a result promotes angiogenesis.

3.2. OVA66 promotes tumour angiogenesis, growth, and metastasis in vivo

To verify the in vitro data, we next determined whether OVA66 overexpression promotes VEGF expression by tumour cells in vivo. OVA66-knockdown HeLa cells or OVA66-overexpressing HO8910 cells were injected subcutaneously into nude mice, tumour growth was monitored, and excised tumours were analysed. As shown in Fig. 2A, cancer cells with high OVA66 expression tend to generate bigger tumours. Consistently, more Ki67+ cells were detectable in xenografts with higher OVA66 expression. To detect angiogenesis, we examined expression of CD31, an endothelial cell marker, and VEGF in tumour sections by IHC staining. Indeed, tumours derived from OVA66-knockdown HeLa cells exhibited significantly reduced VEGF expression and microvessel density compared with tumours derived from NC-shRNA-expressing cells (Fig. 2B, D). Conversely, VEGF expression and microvessel density were both higher in HO8910 tumours overexpressing OVA66 than in the corresponding control tumours (Fig. 2C, E). These results strongly suggest that OVA66 promotes VEGF secretion and angiogenesis of ovarian and cervical cancer cells in vivo.

3.3. OVA66 enhances autocrine VEGF–VEGFR2 signalling in cancer cells

To investigate the mechanism by which OVA66 promotes VEGF expression, we performed a phospho-proteomics-based study using a
high-throughput receptor tyrosine kinase (RTK) phospho-antibody microarray. The results showed that phosphorylation of multiple receptor tyrosine kinases was altered in OVA66-knockdown cells compared with the control cells; of these, the most significant change was a decrease in phosphorylation of VEGFR2 on tyrosine (Tyr) 1175. Phosphorylation of VEGFR2 on Tyr-951, Tyr1059 and Tyr1214 were also significantly downregulated, but to a lesser extent than Tyr1175 (Fig. 3A, Supplemental Table 1). Given that VEGFR2 is the principal receptor for VEGF signalling and that autocrine VEGF–VEGFR2 signalling induces VEGF secretion in many cell types [10–14], these findings suggest that OVA66 might promote VEGF expression in ovarian and cervical cancer cells by enhancing autocrine signalling through VEGFR2. To investigate this, we performed immunofluorescence staining of p-VEGFR2 in OVA66-knockdown HeLa cells incubated with or without rhVEGF. Notably, although rhVEGF treatment markedly increased p-VEGFR2 levels in control cells, this enhancement was dramatically attenuated by OVA66 knockdown (Fig. 3B).

Next, we examined the effects of rhVEGF on signalling pathways downstream of VEGFR2 in cancer cells with different expression of OVA66. As shown in Fig. 3C–E, rhVEGF stimulation increased the phosphorylated (activated) VEGFR2 as well as multiple downstream kinases, including p-ERK, p-AKT, p-FAK, p-P38, p-SRC, and p-PLCγ, compared with unstimulated cells. These effects were markedly reduced by OVA66 knockdown and, conversely, significantly enhanced by OVA66 overexpression (Fig. 3C, D, E). Taken together, these data demonstrate that OVA66 significantly enhances autocrine VEGF–VEGFR2 signalling in both ovarian and cervical cancer cells.

3.4. Sunitinib attenuates OVA66-mediated enhancement of VEGF secretion, proliferation, and angiogenesis in vitro

To confirm that activation of these downstream events was mediated via VEGF–VEGFR2 signalling, we treated HeLa and HO8910 cells with sunitinib, a multi-target tyrosine kinase inhibitor that blocks VEGFR2, but not VEGFR1/3. As expected, OVA66 overexpression in both cell types significantly increased the appearance of p-VEGFR2, p-ERK1/2, and p-AKT levels after rhVEGF stimulation, whereas OVA66 knockdown had the opposite effect. However, pre-treatment with sunitinib dramatically reduced the rhVEGF-stimulated phosphorylation of VEGFR2, ERK1/2 and AKT, to levels comparable to those observed in OVA66-knockdown HeLa cells or HO8910 cells transfected with empty vector (Fig. 4A, B). Taken together, these data indicate that OVA66-induced amplification of autocrine VEGF–VEGFR2 signalling requires VEGFR2 tyrosine kinase activity.

Next, we asked whether OVA66 plays a role in the enhanced cell proliferation and VEGF production stimulated by autocrine VEGF–VEGFR2 signalling in the cancer cells. As expected, rhVEGF treatment increased VEGF secretion by control NC-shRNA-expressing HeLa cells compared with unstimulated cells; however, this effect was markedly reduced by OVA66 knockdown (Fig. 4C). Conversely, OVA66-
overexpressing HO8910 cells produced significantly more VEGF than control cells in response to rhVEGF stimulation (Fig. 4D). Sunitinib treatment abrogated the enhancement of VEGF secretion induced by OVA66 overexpression in both cell lines (Fig. 4C, D; see Supplemental Fig. 2A, B for quantification of VEGF in these experiments). In accordance with these findings, OVA66 promoted VEGF-induced angiogenesis assessed by tube formation by HUVECs in a manner that precisely mirrored the relative VEGF concentrations in each of the supernatants (Fig. 4E, F; see Supplemental Fig. 2C, D for quantification of branch points).

Similarly, we found that OVA66 also played a crucial role in autocrine VEGF–VEGFR2 signalling for cancer cell proliferation. rhVEGF treatment promoted the growth of NC-shRNA HeLa cells and OVA66-overexpressing HO8910 cells; however, the fold change of proliferation rate was significantly reduced or increased by OVA66 knockdown or overexpression, respectively (Fig. 4G, H and Supplemental Fig. 3A, B).

Fig. 2. OVA66 promotes angiogenesis and tumour growth in vivo in xenograft mouse model. (A) OVA66-knockdown HeLa cells or OVA66-overexpressing HO8910 cells were injected subcutaneously into nude mice (BALB/C nu/nu, n = 4 for each group). Tumour size (mm³) was monitored twice a week and tumour weights (g) were measured. Data were showed as the mean size ± SD. Difference of OVA66, Ki67, VEGFA and CD31 expression was analysed by IHC. Representative staining images of xenografts from OVA66 knockdown HeLa cells (B) and OVA66 overexpressed HO8910 cells (C). Histograms of statistical MVD in tumour sections from OVA66-knockdown HeLa cells (D) and OVA66-overexpressed HO8910 cells (E) were shown. Bars represent the number of CD31-positive microvessels (mean ± SD) in three randomly selected fields.
Moreover, sunitinib treatment reduced the proliferation rate of both cell lines to the levels of unstimulated cells (Fig. 4G, H and Supplemental Fig. 3A, B). Interestingly, even in the absence of rhVEGF stimulation, the proliferation of OVA66-knockdown HeLa cells and OVA66-overexpressing HO8910 cells was significantly lower and higher, respectively, than the corresponding control cells (Fig. 4 and Supplemental Fig. 3), which strongly suggests that OVA66 may also be involved in promoting the proliferation of cancer cells through non-VEGF–VEGFR2 pathways.

To confirm these results, we inhibited VEGF–VEGFR2 signalling by transfecting HeLa and HO8910 cells with VEGFR2-specific or scrambled siRNA. Indeed, VEGFR2 silencing abolished rhVEGF-stimulated phosphorylation of VEGFR2, ERK1/2, and AKT in OVA66-knockdown and control HeLa cells as well as in OVA66-overexpressing and control
Consistent with these effects, VEGFR2-specific siRNA also abolished rhVEGF-induced VEGF secretion by the same cells (Supplemental Fig. 5C, D). Thus, the observed effects of OVA66 upregulation or downregulation are mediated through an autocrine VEGF–VEGFR2 positive-feedback signalling loop in ovarian and cervical cancer cells.

3.5. OVA66 increases the migratory and metastatic potential of cancer cells in vitro and in vivo

We previously demonstrated that OVA66 overexpression can promote the migration of ovarian, breast and hepatic cancer cells [22]. Therefore, we next investigated whether it depends on autocrine VEGF–VEGFR2 signalling. Using in vitro Transwell chemotaxis assays, we found that OVA66 overexpression in HO8910 cells and knockdown in HeLa cells significantly increased and decreased, respectively, cell migration under both control and rhVEGF stimulation conditions (Fig. 5A). In addition, rhVEGF-induced stimulation of migration was abolished in the presence of sunitinib treatment (Fig. 5B), confirming that OVA66-mediated regulation of migration required VEGFR2 signalling.

To further explore the effects on migration, we examined tumour metastasis in vivo. OVA66-knockdown or control HeLa cells were injected intravenously into two groups of nude mice, which were administered with sunitinib (100 mg/kg) or vehicle daily for the following 3 weeks. The mice were then sacrificed and the lungs were excised for analysis. We found that the number of lung metastases was significantly lower in mice injected with cells expressing OVA66-shRNA compared with NC-shRNA (Fig. 5C). Sunitinib administration dramatically reduced...

**Fig. 4.** OVA66 amplifies autocrine VEGF-VEGFR2 signalling induced VEGF production, angiogenesis and proliferation of cancer cells. OVA66-knockdown HeLa cells (A) and OVA66-overexpression HO8910 cells (B) were starved and treated with DMSO or Sunitinib followed by rhVEGF stimulation. P-VEGFR2, P-AKT and P-ERK1/2 as well as total VEGFR2, AKT and ERK1/2 were measured by western blot. β-actin was used as the loading control. The results shown are representative of three independent experiments. (C, D) Secreted VEGF concentration in the supernatant was measured by ELISA assay. (E, F) In vitro angiogenesis was assessed by tube formation assay using HUVECs. The result was quantified by number of branch points per field. (G, H) Proliferation of cancer cells was measured by CCK-8 assay. All bar graphs were expressed by fold change relative to corresponding unstimulated group. All samples were analysed in triplicates (unpaired Student’s t-test, mean ± SD, *P < .05, **P < .01, ***P < .001).
the metastasis of both control and OVA66-knockdown HeLa cells, although OVA66 knockdown was more effective than control (Fig. 5C, D). These data indicate that OVA66 overexpression promotes cell migration in vitro and in vivo, at least partly through the autocrine VEGF–VEGFR2 signalling loop.

3.6. OVA66 expression is positively correlated with VEGF expression and disease progression in patients with ovarian cancer

OVA66 is expressed at significantly higher levels in ovarian, colon, and gastric tumour tissues than in normal tissues [18]. To determine whether OVA66 expression correlates with the clinicopathologic characteristics of ovarian cancer patients, we performed IHC staining of a TMA composed of 94 ovarian cancer tissues and 5 normal ovarian tissues [18]. To determine whether OVA66 overexpression promotes cell migration in vitro and in vivo, at least partly through the autocrine VEGF–VEGFR2 signalling loop.

OVA66 is expressed at significantly higher levels in ovarian, colon, and gastric tumour tissues than in normal tissues [18]. To determine whether OVA66 expression correlates with the clinicopathologic characteristics of ovarian cancer patients, we performed IHC staining of a TMA composed of 94 ovarian cancer tissues and 5 normal ovarian tissues. Using the median staining score as the cut-off, we then segregated the patients into two groups based on low and high tumour expression of OVA66. As shown in Table 1, we found that high expression of OVA66 was significantly associated with tumour size (P = .039), advanced stage (P = .020), and distant metastasis (P = .034).

To determine whether a correlation existed between OVA66 and VEGF expression, we also analysed the TMA for VEGF levels. This analysis identified a significant positive correlation between OVA66 and VEGF expression levels (R = 0.314, P = .002; Fig. 6A, B). To confirm this result, we performed pairwise gene correlation analysis between the OVA66 and VEGF gene sets using the Gene Expression Profiling Interactive Analysis website. Consistent with our IHC analysis, significant positive correlations between OVA66 and VEGF expression were identified in both ovarian cancer (R = 0.36, P < .001) and cervical cancer (R = 0.34, P < .001; Fig. 6C, D) datasets.

### Table 1

| Clinicopathologic parameters | OVA66 expression | P value |
|-----------------------------|------------------|--------|
|                             | Low | High |        |
| Total cases                | 46 | 48   | .350  |
| Age (years) ≤60            | 37 | 42   |        |
| >60                        | 9  | 6    |        |
| Histological type          |     |      | .258  |
| Serous cystadenocarcinoma   | 19 | 25   |        |
| Mucinous cystadenocarcinoma | 13 | 7    |        |
| Endometrioid adenocarcinoma| 14 | 16   |        |
| Histologic grade           |     |      | .609† |
| I                          | 13 | 7    |        |
| II                         | 15 | 14   |        |
| III                        | 18 | 27   |        |
| T classification           |     |      | .039† |
| T1                         | 27 | 18   |        |
| T2                         | 11 | 15   |        |
| T3                         | 8  | 15   |        |
| Lymph node metastasis      |     |      | .634* |
| Negative                   | 42 | 46   |        |
| Positive                   | 4  | 2    |        |
| Distant metastasis         |     |      | .034  |
| Negative                   | 40 | 33   |        |
| Positive                   | 6  | 15   |        |
| TNM stage                  |     |      | .020  |
| I–II                       | 37 | 28   |        |
| III–IV                     | 9  | 20   |        |

* P value was calculated by Mantel-Haenszel test.
† P values were calculated by Pearson’s corrected χ² test.
4. Discussion

In this study, we identified a new function for OVA66 in tumour angiogenesis and progression. We found that rhVEGF treatment of ovarian and cervical cancer cells activated VEGFR2 signalling and increased VEGF secretion, confirming the existence of an autocrine VEGF–VEGFR2 feed-forward loop in these cells. We also showed that activation of this loop promoted cancer cell proliferation and migration and acted in a paracrine manner to promote tube formation by endothelial cells. Notably, OVA66-overexpression enhanced rhVEGF-stimulated phosphorylation of VEGFR2 and its downstream signalling components AKT and ERK1/2, as well as VEGF secretion, proliferation, and migration in vitro, all of which were also blocked by sunitinib. In addition, sunitinib attenuated the enhancement of lung metastasis caused by OVA66 overexpression in vivo. These data provide strong evidence that OVA66 enhances the autocrine VEGF–VEGFR2 feed-forward loop by increasing VEGF phosphorylation. OVA66 thus synergises with VEGF to play critical roles in angiogenesis and progression of ovarian and cervical cancer.

OVA66 has been shown to function as an oncoprotein in ovarian and cervical cancer [20–22], colorectal cancer [25], and renal cell carcinoma [26,27], and these studies also showed that OVA66 is involved in activating the insulin-like growth factor 1 receptor–ERK1/2 signalling pathway [22,25] and the lissencephaly-1/dynein signalling pathway [26] in these tumours. Here, we confirmed the ability of OVA66 to promote the development of ovarian and cervical cancer, consistent with the observation that OVA66 expression levels are positively associated with metastasis and advanced disease stage in ovarian cancer patients. In addition, in the present study, we uncovered a new mechanism by which OVA66 functions in enhancing autocrine VEGF–VEGFR2 signalling.

In recent years, autocrine VEGF–VEGFR2 signalling has been recognised to contribute to tumourigenesis in angiogenesis-independent and -dependent manners in a wide range of tumour types, including hepatocellular carcinoma, astrocytoma, skin epithelial cancer, ovarian carcinoma, fibrosarcoma, and Barrett’s-associated neoplasm [11–17]. PLC–ERK [12,13], PI3K–mTOR [11], FAK, and AKT [16] have been implicated as dominant pathways/components involved in...
autocrine VEGF–VEGFR2 signalling. Previous studies reported that auto-
cline VEGF–VEGFR2 signalling can be promoted via NRPI-mediated 
stabilisation and recycling of cytosolic VEGFR2 to the plasma mem-
brane [14] and via upregulation of NRPI, VEGFR2, and VEGF expression in 
response to epidermal growth factor receptor signalling [17]. In the 
present study, we found that OVA66 knockdown in SKOV3 ovarian can-
cer cells reduced FBS-induced activation of multiple receptor tyrosine ki-
nases, of which VEGFR2 activation was the most affected. OVA66 over-
expression increased rhVEGF-induced activation of VEGFR2, P38, FAK, 
P38K–AKT, and PLCγ–ERK1/2 pathways, which was abrogated by suniti-
nib treatment. This regulatory function of OVA66 provides novel insight 
into autocrine VEGF signalling.

The role of VEGF in inducing angiogenesis is well characterised. In 
lung cancer, autocrine VEGF–VEGFR2 signalling has been shown to 
promote VEGF production and trigger angiogenesis [11]. In this 
study, we showed that OVA66 overexpression increases VEGF pro-
duction by cancer cells in vitro and in vivo in a VEGFR2 signalling-
dependent manner. Using experimental and bioinformatics ap-
proaches, we demonstrated that OVA66 and VEGF expression is pos-
tsively associated in human ovarian cancer specimens, which is 
consistent with our observation that elevated OVA66 expression in-
terupted tumour angiogenesis in vitro and in vivo. Taken together, our 
results demonstrate that high OVA66 levels promote VEGF produc-
tion and angiogenesis by enhancing an autocrine VEGF–VEGFR2 feed-
forward loop.

Earlier studies demonstrated that autocrine VEGF–VEGFR2 signal-
ing can promote cancer cell proliferation [12,13,17] and protect against 
apoptosis [15,16] in an angiogenesis-independent manner. Here, we 
showed that ovarian and cervical cancer cells overexpressing OVA66 ex-
hibited enhanced rhVEGF-stimulated proliferation and migration, 
which were inhibited by sunitinib. To our knowledge, this is the first re-
port that OVA66 promotes the migration of ovarian and cervical cancer 
cells depending on autocrine VEGF–VEGFR2 signalling.

In summary, we found that high OVA66 levels increase activation of 
an autocrine VEGF–VEGFR2 feed-forward loop by enhancing VEGFR2 
phosphorylation, and that this promotes tumour progression via an au-
tocrine mechanism and also promotes angiogenesis via a paracrine 
mechanism (Fig. 6E). Our results identify a potential new strategy for 
combining OVA66-targeted therapy with anti-angiogenic therapy to 
achieve synergistic effects on ovarian and cervical cancer.

Acknowledgements

We thank Anne M. O’Rourke, PhD, from Liwen Bianji, Edanz Group 
China (www.liwenbianji.cn/ac), for editing the English text of a draft 
of this manuscript.

Funding sources

This work was supported by grants from the National Natural Sci-
ence Foundation of China (81602262); and Excellent Young Scholar Pro-
ject; and QW designed the project and the experiments, analysed 
the data, and reviewed the manuscript.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ebiom.2019.02.051.

References

[1] Masoomi Moghaddam S, Aminia A, Morris DL, Pourgholami MH. Significance of 
vascular endothelial growth factor in growth and peritoneal dissemination of ovarian 
cancer. Cancer Metastasis Rev 2012 Jun;31(1–2):143–62.
[2] Tewari KS, Sill MW, Penson PT, Huang H, Ramondetta LM, Landrum LM, et al. 
Bevacizumab for advanced cervical cancer: final overall survival and adverse event 
analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncol 
Group 240). Lancet 2017 Oct 7;389(10103):1654–63.
[3] Oza AM, Cook AD, Pfisterer J, Embleton AC, Ledermann JA, Pujade-Lauraine E, et al. 
Standard chemotheraphy with or without bevacizumab for women with newly diag-
nosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. 
Lancet Oncol 2015 Aug 1;16(8):928–36.
[4] Monik BJ, Mas Lopez L, Zarba JJJ, Aaknin A, Targin C, Termurungraunglert W, et al. 
Phase II, open-label study of pazopanib or lapatinib monotherapy compared with 
Pazopanib plus Lapatinib combination therapy in patients with advanced and recurrent 
cervical cancer. J Clin Oncol 2010 Aug 1;28(22):3562–9.
[5] Ledermann JA, Embleton AC, Raja F, Perren TJ, Jayson GC, Rustin GS, et al. Cediranib in 
patients with relapsed platinum-resistant ovarian cancer (ICON6): a randomised, 
double-blind, placebo-controlled phase 3 trial. Lancet 2016 Mar 12;387(10023): 
1066–74.
[6] Goel HL, Mercurio AM. VEGF targets the tumour cell. Nat Rev Cancer 2013 Dec 13; 
13(1):47–52.
[7] Barr MP, Gray SG, Gately K, Hams E, Fallon PG, Davies AM, et al. Vascular endothelial 
growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-
small cell lung cancer. Mol Cancer 2015 Feb 10;14:45.
[8] Cao X, Guanqiu Y, Wang E, Pal K, Dutta SK, Bar-Sagi D, et al. VEGF exepts an 
angiogenesis-independent function in cancer cells to promote their malignant 
progression. Cancer Res 2012 Aug 15;72(16):3912–8.
[9] Perrin-Applanat M, Benedetto MD. Autocrine functions of VEGF in breast tumor 
cells; adhesion, survival, migration and invasion. Cell Adhes Migr 2012 Nov 17(6): 
547–53.
[10] Golffmann K, Meder L, Köker M, Volz C, Borchmann S, Tharun L, et al. Synergistic anti-
angiogenic treatment effects by dual FGFR1 and VEGF inhibition in FGFR1-
amplified breast cancer. Oncogene 2018 Jul;37:1.
[11] Chatterjee S, Heukamp LC, Siobal M, Schöttle J, Wieczorek C, Peifer M, et al. Tumor 
VEGF–VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. J 
Clin Invest 2013 Apr 1;123(4):1732–40.
[12] Zhang Q, Yu C, Peng S, Xu H, Wright E, Zhang X, et al. Autocrine VEGF signaling pro-
motes proliferation of neoplastic Barrett’s epithelial cells through a PLC-dependent 
pathway. Gastroenterology 2014 Feb 1;146(2):461–472.e6.
[13] Peng S, Wang Y, Peng H, Chen D, Shen S, Peng B, et al. Autocrine vascular endo-
thelial growth factor signaling promotes cell proliferation and modulates 
sorafenib treatment efficacy in hepatoceular carcinoma. Hepatology 2014;60(4): 
1264–77.
[14] Hamerlik P, Latthia JD, Rasmussen R, Wu Q, Bartlott J, Lee M, et al. Autocrine VEGF– 
VEGFR2–Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor 
growth. J Exp Med 2012 Mar 12;209(3):507–20.
[15] Sher L, Adham SA, Petrik J, Coonber BL. Autocrine VEGF-A/KDR loop protects ep-
ithelial ovarian carcinoma cells from anoxia. Int J Cancer 2009 Feb 1;124(3): 
553–61.
[16] Lee J, Ku T, Yu H, Chung K, Ryu S-W, Choi K, et al. Blockade of VEGF-A suppresses 
tumor growth via inhibition of autocrine signaling through FAK and AKT. Cancer 
Lett 2012 May 28;318(2):221–5.
[17] Lichtenberger BM, Tan PK, Niederleithner H, Ferrara N, Petzelbauer P, Sibilia M. Au-
tocrine VEGF Signaling synergizes with EGFR in tumor cells to promote epithelial 
Cancer development. Cell 2010 Jan 22;140(2):268–78.
[18] Jin S, Wang Y, Zhang Y, Zhang H-Z, Wang S-J, Tang J-Q, et al. Humoral immune re-
sponses against tumor-associated antigen OVA66 originally defined by serological 
analysis of recombinant CDNA expression libraries and its potentiality in cellular im-
munity. Cancer Sci 2008 Aug;59(8):1570–8.
[19] Yang X-F, Wu CJ, McLaughlin S, Chillemi A, Wang KS, Canning C, et al. CML66, a 
broadly immunogenic tumor antigen, elicits a humoral immune response associated 
with remission of chronic myelogenous leukemia. Proc Natl Acad Sci 2001 Jun 19; 
98(12):7462–7.
[20] Wang Q, Li M, Wang Y, Zhang J, Yin Q, Wang Y, et al. OVA66 induces cell growth, in-
vasiveness and survival via regulation of IGF-IR–MAPK signalling in human cancer cells. 
Carcinogenesis 2014 Jul 1;35(7):1573–81.
[23] GEPIA (Gene Expression Profiling Interactive Analysis). [Internet]. [cited 2018 Jan 15]. Available from: http://gepia.cancer-pku.cn/.

[24] Tang Z, Li C, Kang B, Gao C, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res 2017 Jul 3;45 (W1):W98–102.

[25] Han B, Zhang Y-Y, Xu K, Bai Y, Wan L-H, Miao S-K, et al. NUDCD1 promotes metastasis through inducing EMT and inhibiting apoptosis in colorectal cancer. Am J Cancer Res 2018 May 1;8(5):810–23.

[26] He H, Dai J, Wang X, Qian X, Zhao J, Wang H, et al. NudCD1 affects renal cell carcinoma through regulating LIS1/dynein signaling pathway. Am J Transl Res 2018 Feb 15;10(2):519–24.

[27] Wang R-J, Wang N, Cui C, Chen Y, Zhong H, Tang J. The impact of NudCD1 on renal carcinoma cell proliferation, migration, and invasion. Eur Rev Med Pharmacol Sci 2018 Feb;22(3):671–7.